PERIMEDI® is Koreas first preion-only, non-surgical combination antibiotic ointment developed for the treatment of peri-implantitis and moderate-to-severe periodontitis, formulating Minocycline and Metronidazole.Overcoming the limitations of conventional single-agent antibiotics, it simultaneously eradicates both anaerobic and aerobic bacteria—the primary pathogens of periodontal disease. Engineered with proprietary formulation technology, it ensures superior mucoadhesion and extended drug retention even within deep periodontal pockets.Demonstrated through extensive domestic Phase 3 clinical trials, PERIMEDI® showed a 1.8-fold faster therapeutic response compared to the control drug, along with significant reductions in periodontal pocket depth (PPD), bleeding on probing (BOP), and bone loss—providing an effective non-surgical treatment option to resolve inflammation prior to surgical intervention.